KR20180111797A - 퀴놀론 유사체의 결정형 및 그것의 염 - Google Patents

퀴놀론 유사체의 결정형 및 그것의 염 Download PDF

Info

Publication number
KR20180111797A
KR20180111797A KR1020187020110A KR20187020110A KR20180111797A KR 20180111797 A KR20180111797 A KR 20180111797A KR 1020187020110 A KR1020187020110 A KR 1020187020110A KR 20187020110 A KR20187020110 A KR 20187020110A KR 20180111797 A KR20180111797 A KR 20180111797A
Authority
KR
South Korea
Prior art keywords
crystalline form
cancer
compound
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187020110A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 엠. 라이크맨
이칭 그레이스 유
흐시오우-팅 리우
Original Assignee
센화 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센화 바이오사이언시즈 인코포레이티드 filed Critical 센화 바이오사이언시즈 인코포레이티드
Publication of KR20180111797A publication Critical patent/KR20180111797A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020187020110A 2015-12-14 2015-12-14 퀴놀론 유사체의 결정형 및 그것의 염 Ceased KR20180111797A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/065443 WO2017105382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Publications (1)

Publication Number Publication Date
KR20180111797A true KR20180111797A (ko) 2018-10-11

Family

ID=59057173

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020110A Ceased KR20180111797A (ko) 2015-12-14 2015-12-14 퀴놀론 유사체의 결정형 및 그것의 염

Country Status (10)

Country Link
EP (2) EP4249072A3 (https=)
JP (1) JP2018537486A (https=)
KR (1) KR20180111797A (https=)
CN (1) CN108699083A (https=)
AU (2) AU2015417382A1 (https=)
CA (2) CA3006502A1 (https=)
ES (1) ES2959536T3 (https=)
IL (1) IL260004A (https=)
RU (1) RU2018124599A (https=)
WO (1) WO2017105382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CA3129722A1 (en) * 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
CA3151116A1 (en) * 2019-08-14 2021-02-18 Hshiou-Ting Liu Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
EP4013421A4 (en) * 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN118005653B (zh) * 2023-04-23 2024-12-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034113A2 (en) * 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
ES2754207T3 (es) * 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos

Also Published As

Publication number Publication date
JP2018537486A (ja) 2018-12-20
EP3394070A1 (en) 2018-10-31
CN108699083A (zh) 2018-10-23
AU2021203085A1 (en) 2021-06-10
EP3394070B1 (en) 2023-08-02
EP4249072A2 (en) 2023-09-27
IL260004A (en) 2018-07-31
EP3394070A4 (en) 2019-05-08
AU2015417382A1 (en) 2018-06-14
ES2959536T3 (es) 2024-02-26
AU2021203085B2 (en) 2023-06-08
EP4249072A3 (en) 2023-10-25
CA3255938A1 (en) 2025-11-28
RU2018124599A (ru) 2020-01-16
CA3006502A1 (en) 2017-06-22
EP3394070C0 (en) 2023-08-02
WO2017105382A1 (en) 2017-06-22
RU2018124599A3 (https=) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2021203085B2 (en) Crystalline forms of quinolone analogs and their salts
TWI597282B (zh) ６，７-不飽合-７-胺甲醯基嗎啡喃衍生物之結晶及其製造方法
AU2017254982A1 (en) Process for preparing quinoline derivatives
TW201202228A (en) Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
TW201706249A (zh) 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
JP2013540759A (ja) 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CN102264726B (zh) 舒尼替尼盐
WO2009121228A2 (zh) 鲁比前列酮晶体、其制备方法及用途
JP6657294B2 (ja) ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2025507196A (ja) 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
CN106674294A (zh) 吡喃葡萄糖基衍生物的结晶形式
CN101277694B (zh) 盐酸伊立替康的新晶形
JP2015535842A (ja) ニューロトロフィン模倣化合物の結晶形及びその塩
US11225467B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
JP2022179783A (ja) キノロン類似体及びその塩の結晶形
TW202115091A (zh) 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts
HK1212970B (en) Crystalline forms of neurotrophin mimetic compounds and their salts
HK1177152A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221024

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230502

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221024

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I